LifeSci Capital initiated coverage of Molecular Partners (MOLN) with an Outperform rating and $12 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOLN:
- Molecular Partners AG: Strong Financials and Promising Pipeline Justify Buy Rating
- Molecular Partners AG: Strategic Advances and Financial Overview
- Molecular Partners and Orano Med Expand Cancer Therapy Collaboration
- Molecular Partners Expands Radio-DARPin Pipeline and Advances Clinical Trials at Healthcare Conference